scroll
UP

Type 1 Diabetes
Clinical Trial

Baricitinib in new onset type 1 diabetes
(the BANDIT trial)

About the trial

Researchers at St Vincent’s Institute in Melbourne (SVI) have discovered that a drug called baricitinib may help people who have type 1 diabetes to produce insulin for longer after diagnosis. It is expected to stop the immune system from attacking the insulin-producing cells in the pancreas. There are no approved treatments that are able to do this. 

Baricitinib is approved around the world for patients with rheumatoid arthritis. In a global first, the BANDIT trial will test baricitinib's effectiveness for people recently diagnosed with type 1 diabetes.

The BANDIT trial is supported by JDRF Australia and JDRF International.

Participant recruitment

Thanks to the generosity of the type 1 diabetes community, we have finished recruiting participants for the BANDIT trial. 

We hope to begin sharing information about the findings of the BANDIT trial in 2023.

To stay informed, please visit our website, or follow us on Facebook, Twitter or LinkedIn

Information about other clinical trials 

The IMPACT Trial

If you are aged over 18 years – 45 years and have recently been diagnosed with type 1 diabetes you may be able to join the IMPACT trial.

This trial has been set up to see if the test drug can enable a person’s own immune system to stop the destruction of insulin-producing cells in the pancreas.
Currently, eligible participants can attend a trial site in Melbourne and sites in Sydney and Brisbane will soon be available.

For more information refer to this flyer, or view this video.

If you think you may be eligible for this trial and are interested in participating, please email the study team at: [email protected]

Links to external clinical trial sites

To find out about other clinical trial opportunities in Australia, you can visit: 

To find out about other type 1 diabetes clinical trial opportunities happening globally, you can visit: 

Each clinical trial will have its own specific eligibility guidelines. We recommend you contact the trial managers or clinical trial site personnel for more information on specific trials. 

Join our contact list 

St Vincent’s Institute will be involved in future clinical trials for people with type 1 diabetes. 

To express your interest to participate in future trials, please enquire here.